Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.40USD
15 Dec 2017
Change (% chg)

$0.12 (+2.80%)
Prev Close
$4.28
Open
$4.29
Day's High
$4.41
Day's Low
$4.22
Volume
668,405
Avg. Vol
286,677
52-wk High
$9.85
52-wk Low
$4.20

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

09 Nov 2017

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

02 Nov 2017

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

05 Oct 2017

Zika vaccine shows promise in early human trial

CHICAGO A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc and South Korea's GeneOne Life Science Inc induced anti-Zika immune responses in an early stage human trial, U.S. researchers reported on Wednesday.

05 Oct 2017

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

18 Sep 2017

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

11 Sep 2017

BRIEF-Inovio Pharmaceuticals reports Q2 loss per share $0.13

* Inovio Pharmaceuticals reports 2017 second quarter financial results

09 Aug 2017

BRIEF-Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share

* Inovio announces pricing of public offering of common stock

20 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.46 +0.81
Novartis AG (NOVN.S) CHF83.80 -0.05
Pfizer Inc. (PFE.N) $37.20 +0.74
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Sanofi SA (SASY.PA) €73.55 -0.22
GlaxoSmithKline plc (GSK.L) 1,295.00 +4.50
AstraZeneca plc (AZN.L) 4,881.00 -3.50

Earnings vs. Estimates